PGR Petition Alleges Gilead Sciences Made Inconsistent Section 112 Arguments
IP Watchdog
AUGUST 27, 2023
This past week, IPWatchdog was made aware of a petition for post-grant review (PGR) proceedings at the Patent Trial and Appeal Board (PTAB) that raises interesting arguments about allegedly inconsistent statements on patentability made during legal proceedings by pharmaceutical firm, Gilead Sciences. Filed in early August, the PGR petition from Atea Pharmaceuticals cites 35 U.S.C. § 112 arguments previously raised by Gilead in other cases to challenge the validity of Gilead’s own patent claims t
Let's personalize your content